Wall Street brokerages forecast that NewLink Genetics Corp (NASDAQ:NLNK) will announce $2.72 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for NewLink Genetics’ earnings. The lowest sales estimate is $300,000.00 and the highest is $5.00 million. NewLink Genetics reported sales of $12.70 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 78.6%. The company is expected to issue its next quarterly earnings report on Tuesday, February 27th.
According to Zacks, analysts expect that NewLink Genetics will report full-year sales of $2.72 million for the current fiscal year, with estimates ranging from $18.61 million to $23.60 million. For the next fiscal year, analysts expect that the business will post sales of $12.20 million per share, with estimates ranging from $1.10 million to $20.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that that provide coverage for NewLink Genetics.
A number of equities research analysts have recently commented on the company. Zacks Investment Research downgraded NewLink Genetics from a “buy” rating to a “hold” rating in a research report on Thursday. BidaskClub upgraded NewLink Genetics from a “sell” rating to a “hold” rating in a research report on Friday. ValuEngine downgraded NewLink Genetics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 26th. Jefferies Group upgraded NewLink Genetics from a “hold” rating to a “buy” rating and increased their price objective for the company from $7.00 to $26.00 in a research report on Friday, September 8th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $26.00 price objective on shares of NewLink Genetics in a research report on Monday, September 25th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $23.29.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company lifted its holdings in shares of NewLink Genetics by 3.0% in the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 556 shares in the last quarter. Advisor Group Inc. lifted its holdings in shares of NewLink Genetics by 3.4% in the second quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock valued at $133,000 after purchasing an additional 600 shares in the last quarter. First Trust Advisors LP lifted its holdings in shares of NewLink Genetics by 11.1% in the second quarter. First Trust Advisors LP now owns 28,598 shares of the biotechnology company’s stock valued at $210,000 after purchasing an additional 2,859 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in shares of NewLink Genetics by 1.8% in the second quarter. Wells Fargo & Company MN now owns 165,791 shares of the biotechnology company’s stock valued at $1,219,000 after purchasing an additional 2,865 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of NewLink Genetics by 1.2% in the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock valued at $2,875,000 after purchasing an additional 4,630 shares in the last quarter. Institutional investors own 52.63% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Expect NewLink Genetics Corp (NLNK) Will Announce Quarterly Sales of $2.72 Million” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/01/06/zacks-brokerages-expect-newlink-genetics-corp-nlnk-will-announce-quarterly-sales-of-2-72-million.html.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.